These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10705872)

  • 1. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients.
    Yazici H; Dolapcioglu K; Buyru F; Dalay N
    Cancer Invest; 2000; 18(2):110-4. PubMed ID: 10705872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
    Wu JT; Astill ME; Gagon SD; Bryson L
    J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of serum c-erbB-2 oncoprotein, insulin-like growth factor-1 and vascular endothelial growth factor levels in ovarian cancer.
    Akcay T; Yasar O; Kuseyri MA; Dincer Y; Aydinli K; Benian A; Balcan E; Erenel H
    Bratisl Lek Listy; 2016; 117(3):156-60. PubMed ID: 26925746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy.
    Meden H; Marx D; Fattahi A; Rath W; Kron M; Wuttke W; Schauer A; Kuhn W
    J Cancer Res Clin Oncol; 1994; 120(6):378-81. PubMed ID: 7908021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
    Mabrouk RA; Ali-Labib R
    Clin Biochem; 2003 Oct; 36(7):537-43. PubMed ID: 14563447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
    McKenzie SJ; DeSombre KA; Bast BS; Hollis DR; Whitaker RS; Berchuck A; Boyer CM; Bast RC
    Cancer; 1993 Jun; 71(12):3942-6. PubMed ID: 8099528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative measurement of c-erbB-2 p185 and mutant p53 expression in ovarian neoplasms by enzyme immunoassay.
    Mabrouk GM; Helal SA; El-Lamie KI; Khalifa A
    Clin Chem; 1996 Jun; 42(6 Pt 1):981-2. PubMed ID: 8665697
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship between p53 and c-erbB-2 overexpression in tissue sections and cyst fluid cells of patients with ovarian cancer.
    Harłozińska A; Bar JK
    Tumour Biol; 1994; 15(4):223-9. PubMed ID: 7939171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of serum c-erbB-2 in patients with ovarian masses.
    Cheung TH; Wong YF; Chung TK; Maimonis P; Chang AM
    Gynecol Obstet Invest; 1999; 48(2):133-7. PubMed ID: 10461006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors.
    Kim YT; Kim JW; Lee JW
    Cancer Lett; 1998 Oct; 132(1-2):91-7. PubMed ID: 10397458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms.
    Harlozińska A; Bar JK; Sobańska E; Goluda M
    Tumour Biol; 1998; 19(5):364-73. PubMed ID: 9701727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer.
    Chariyalertsak S; Sugano K; Ohkura H; Mori Y
    Tumour Biol; 1994; 15(5):294-303. PubMed ID: 7991990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.
    Wang DP; Konishi I; Koshiyama M; Nanbu Y; Iwai T; Nonogaki H; Mori T; Fujii S
    Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):393-400. PubMed ID: 1360720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [C-erbB-2 protein in ovarian epithelial cancer: correlation between expression in tumor tissue and blood levels].
    Felip E; Encabo G; Vidal MT; Vera R; del Campo JM; Rubio D
    Med Clin (Barc); 1995 Jun; 105(1):5-8. PubMed ID: 7637419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.
    Meden H; Kuhn W
    Eur J Obstet Gynecol Reprod Biol; 1997 Feb; 71(2):173-9. PubMed ID: 9138962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum c-erB-2 levels in monitoring of operable breast cancer patients.
    Imoto S; Kitoh T; Hasebe T
    Jpn J Clin Oncol; 1999 Jul; 29(7):336-9. PubMed ID: 10470658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Muñoz M; Farrus B; Latre ML; Gimenez N; Hage M; Estape J; Ballesta AM
    Anticancer Res; 1996; 16(4B):2295-300. PubMed ID: 8694559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer.
    Meden H; Marx D; Schauer A; Wuttke W; Kuhn W
    Anticancer Res; 1997; 17(1B):757-60. PubMed ID: 9066616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.
    Isola JJ; Holli K; Oksa H; Teramoto Y; Kallioniemi OP
    Cancer; 1994 Feb; 73(3):652-8. PubMed ID: 7905363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.